FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2925163911> ?p ?o ?g. }

• W2925163911 abstract "Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have a poor prognosis. Over the past decade, a major development in the first-line treatment of R/M SCCHN was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy. Currently, a promising novel treatment option in R/M SCCHN has emerged, termed immune checkpoint inhibitors. However, only a few patients presenting with R/M SCCHN have exhibited meaningful tumor regression with these agents. Therefore, novel agents are required to order improve the overall survival of patients with R/M SCCHN. Recently, we demonstrated that R/M SCCHN cells are highly sensitive to eribulin. In the present study, the effects of eribulin, paclitaxel and vinblastine were investigated in R/M SCCHN (OLC-01 and OSC-19) and locally advanced SCCHN (OSC-20) cells. Tumour-inhibitory activities of eribulin against R/M SCCHN were evaluated in orthotopic xenograft models. The data revealed that eribulin has sub-nM growth inhibitory activities in vitro against OLC-01 cells, and that it is more potent than paclitaxel and vinblastine. The reduced expression of Tubulin Beta 3 Class III (TUBB3) following treatment was correlated with a high sensitivity to eribulin. Histological analysis of OLC-01 cells in NOD-SCID mice demonstrated that they had a higher invasiveness in the tissue around the alveolar cancer when compared with the histology of OSC-19 cells, which has been reported in our previous study. Treatment with eribulin revealed marked inhibitory activities in vivo at 0.125 mg/kg against OLC-01 cells orthotopic xenografts. In conclusion, the results highlight the existence of invasive-type heterogeneity in R/M SCCHN with respect to eribulin sensitivity. Eribulin is already an approved clinical agent; therefore, the continued investigation of its preclinical antitumor attributes may contribute significantly to the future process of identifying novel uses of eribulin against R/M SCCHN." @default.
• W2925163911 created "2019-04-01" @default.
• W2925163911 creator A5002063778 @default.
• W2925163911 creator A5006542515 @default.
• W2925163911 creator A5018169873 @default.
• W2925163911 creator A5018930499 @default.
• W2925163911 creator A5050654492 @default.
• W2925163911 creator A5061345986 @default.
• W2925163911 creator A5065436629 @default.
• W2925163911 creator A5091081425 @default.
• W2925163911 creator A5091177614 @default.
• W2925163911 date "2019-03-19" @default.
• W2925163911 modified "2023-10-11" @default.
• W2925163911 title "Selectively high efficacy of eribulin against high‑grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck" @default.
• W2925163911 cites W1858568413 @default.
• W2925163911 cites W1885901959 @default.
• W2925163911 cites W1946296350 @default.
• W2925163911 cites W1971579914 @default.
• W2925163911 cites W1971989695 @default.
• W2925163911 cites W2003643844 @default.
• W2925163911 cites W2018563247 @default.
• W2925163911 cites W2019684848 @default.
• W2925163911 cites W2028144293 @default.
• W2925163911 cites W2048422149 @default.
• W2925163911 cites W2069289573 @default.
• W2925163911 cites W2079678302 @default.
• W2925163911 cites W2081938650 @default.
• W2925163911 cites W2102838762 @default.
• W2925163911 cites W2107277218 @default.
• W2925163911 cites W2112845420 @default.
• W2925163911 cites W2118991777 @default.
• W2925163911 cites W2123851255 @default.
• W2925163911 cites W2132445915 @default.
• W2925163911 cites W2137545466 @default.
• W2925163911 cites W2140818354 @default.
• W2925163911 cites W2165385965 @default.
• W2925163911 cites W2166928434 @default.
• W2925163911 cites W2253019052 @default.
• W2925163911 cites W2297144460 @default.
• W2925163911 cites W2529484692 @default.
• W2925163911 cites W2537234361 @default.
• W2925163911 cites W2561843661 @default.
• W2925163911 cites W2605497049 @default.
• W2925163911 cites W2701417396 @default.
• W2925163911 cites W2711613673 @default.
• W2925163911 cites W2763009064 @default.
• W2925163911 cites W2772261825 @default.
• W2925163911 cites W2790560905 @default.
• W2925163911 cites W2803671385 @default.
• W2925163911 cites W1964184380 @default.
• W2925163911 doi "https://doi.org/10.3892/ol.2019.10165" @default.
• W2925163911 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6507455" @default.
• W2925163911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31186718" @default.
• W2925163911 hasPublicationYear "2019" @default.
• W2925163911 type Work @default.
• W2925163911 sameAs 2925163911 @default.
• W2925163911 citedByCount "1" @default.
• W2925163911 countsByYear W29251639112023 @default.
• W2925163911 crossrefType "journal-article" @default.
• W2925163911 hasAuthorship W2925163911A5002063778 @default.
• W2925163911 hasAuthorship W2925163911A5006542515 @default.
• W2925163911 hasAuthorship W2925163911A5018169873 @default.
• W2925163911 hasAuthorship W2925163911A5018930499 @default.
• W2925163911 hasAuthorship W2925163911A5050654492 @default.
• W2925163911 hasAuthorship W2925163911A5061345986 @default.
• W2925163911 hasAuthorship W2925163911A5065436629 @default.
• W2925163911 hasAuthorship W2925163911A5091081425 @default.
• W2925163911 hasAuthorship W2925163911A5091177614 @default.
• W2925163911 hasBestOaLocation W29251639111 @default.
• W2925163911 hasConcept C121608353 @default.
• W2925163911 hasConcept C126322002 @default.
• W2925163911 hasConcept C143998085 @default.
• W2925163911 hasConcept C2775930923 @default.
• W2925163911 hasConcept C2776387010 @default.
• W2925163911 hasConcept C2776530083 @default.
• W2925163911 hasConcept C2776694085 @default.
• W2925163911 hasConcept C2777132456 @default.
• W2925163911 hasConcept C2777292972 @default.
• W2925163911 hasConcept C2779998722 @default.
• W2925163911 hasConcept C502942594 @default.
• W2925163911 hasConcept C526805850 @default.
• W2925163911 hasConcept C530470458 @default.
• W2925163911 hasConcept C71924100 @default.
• W2925163911 hasConceptScore W2925163911C121608353 @default.
• W2925163911 hasConceptScore W2925163911C126322002 @default.
• W2925163911 hasConceptScore W2925163911C143998085 @default.
• W2925163911 hasConceptScore W2925163911C2775930923 @default.
• W2925163911 hasConceptScore W2925163911C2776387010 @default.
• W2925163911 hasConceptScore W2925163911C2776530083 @default.
• W2925163911 hasConceptScore W2925163911C2776694085 @default.
• W2925163911 hasConceptScore W2925163911C2777132456 @default.
• W2925163911 hasConceptScore W2925163911C2777292972 @default.
• W2925163911 hasConceptScore W2925163911C2779998722 @default.
• W2925163911 hasConceptScore W2925163911C502942594 @default.
• W2925163911 hasConceptScore W2925163911C526805850 @default.
• W2925163911 hasConceptScore W2925163911C530470458 @default.
• W2925163911 hasConceptScore W2925163911C71924100 @default.
• W2925163911 hasLocation W29251639111 @default.
• W2925163911 hasLocation W29251639112 @default.
• W2925163911 hasLocation W29251639113 @default.

• next